The residue of solvent in APIs is one of the key issues to be mindful of during drug manufacturing. When solvent residue exists in the APIs or formulations, it may have adverse effects on the stability, purity, and efficacy of the drugs. Overcoming the difficulties of solvent residue in APIs involves multiple aspects, such as selecting appropriate solvents, optimizing synthesis conditions, and employing effective methods for solvent removal. At the same time, it is essential to employ scientific testing methods to monitor and ensure that solvent residues are within acceptable limits. Establishing highly sensitive and accurate analytical detection methods is indispensable to meet international standards for residual solvent detection, thus safeguarding the safety and efficacy of medication for patients.
The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study
Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

评论
发表评论